Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Approved for marketing × Thyroid Neoplasms × lenvatinib × Clear all

Status

Completed 6 Recruiting 2 Approved for marketing 2 Unknown 1 Terminated 1 Suspended 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Expanded_access 2

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03533361 2018-12-17

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Eisai Inc.

Approved for marketing

Thyroid Neoplasms

NCT02211222 2016-03-16

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Inc.

Approved for marketing

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡